




## Advancing Patients' Care

PacePress | CoolCryo | MiniMax | AtriClamp

Corporate presentation  
December 2025



***We develop advanced solutions  
to support patients with cardiovascular diseases***



## LEGAL NOTICE

This document has been prepared for information purposes only. It does not constitute an advertisement or offer of securities in public trading. It uses sources of information that Medinice S.A. considers as reliable and accurate, but there is no guarantee that they are comprehensive and fully reflect the facts.

The study may contain forward-looking statements that represent investment risk or a source of uncertainty and may differ materially from actual results.

Medinice S.A. is not responsible for the effects of decisions that were taken on the basis of this study. Responsibility rests solely with the users of the study. The study is protected by the Act on Copyright and Related Rights. Reproduction, publication or distribution requires the written consent of Medinice S.A..



## WHO WE ARE



**Sanjeev Choudhary**  
*Co-Funder*  
*Chief Executive Officer*

**Piotr Suwalski MD PhD** Proffesor of medicinice  
*Co-Funder / Co-Inventor*  
*Chairman of the Scientific Board*

Established in 2012 by renowned medical professionals and seasoned entrepreneur.

Innovates, develops, and commercializes advanced cardiovascular care technologies.

Listed on the Warsaw Stock Exchange since 2018.

Holds ISO 13485 and CE MDR for PacePress.

CoolCryo FDA 510(k) ongoing Substantive Review.

The 510(k) pathway was confirmed with the FDA for the Atriclamp project.

17 PLN  
milions

obtained from  
grants

60+

patents and  
applications

55 PLN  
milions

obtained from the  
issue of shares

4

implemented  
projects

589 PLN  
milions

value of projects\*

25%  
founders

75%  
free float

\* In 2023, D.M. INC prepared a project valuation of PLN 589 million.

\* In 2021, D.M. Trigon prepared an independent project valuation of PLN 323 million.

\*\* As of June 30, 2025, the Group employed 11 people (unchanged from December 31, 2024).





**Sanjeev Choudhary**  
CEO & CO-FOUNDER

Graduate of Wroclaw University of Technology, Ashridge Business School, MBA, INSEAD and Centre for Creative Leadership programmes



**Piotr Suwalski**  
MD PhD Prof  
CO-FOUNDER CO-INVENTOR

First LAAO in 2009 in Poland. The only surgeon in Europe with 500+ robotic surgeries. Member of 21st Century Club Ex-President of the ISMICS.



**Piotr Lozinski**  
CFO

15+ years of experience Finance in FMCG and medical devices sectors. M&A advisory. Successful equity and debt rounds. Fellow member of ACCA and Institute of Internal Auditors



**Greg Wróblewski**  
Med. Eng. PhD  
CTO

Inventor of technology integrated by Medtronic. Developed 4 medical devices (2nd and 3rd class), 15+ years of experience in R&D, >50 scientific papers

**CARDIAC SURGERY**

**Piotr  
Suwalski  
MD, PhD, Prof**

Director of National Medical Institute of MIA in Poland. Former president of ISMICS, member of ESC i EACTS, 21CCSS



**Valavanur  
Subramanian  
MD, PhD**

Head of Lenox Hill Cardiac Surgery - Manhattan. Pioneer of minimally invasive cardiac surgery. Founder of ISMICS.



**Paul  
Gründeman  
MD, PhD**

Former Director of the Experimental Cardiothoracic and Vascular Surgery at Utrecht Medical Center. Co-inventor of the Octopus device



**Paweł  
Balsam  
MD, PhD, Prof**

Head of Clinical Electrophysiology Department at WUM, professor of medical sciences, specialist in arrhythmia ablation and cardiovascular disease prevention



**Michael  
Glikson  
MD, PhD, Prof**

Director of Jesselson Integrated Heart Center, professor at Hebrew University and Mayo College, former president of Israel Heart Society



**Adam  
Budzikowski  
MD, PhD**

Downstate Director at SUNY Downstate, New York. Over 30 years of experience in clinical medicine. Member of the PSC and ESC and HRS

**ELECTRO PHYSIOLOGY**



# Pipeline of wide range innovative medical devices

## AtriClamp

epicardial  
LAAO device



**PROTOTYPING**  
R&D

## MiniMax®

RF ablation catheter  
offering 3D mapping  
and cooling



**PRECLINICAL  
TESTING**

## CoolCryo®

quick & powerful  
epi- & endocardial  
cryoablation



**CERTIFICATION**  
Market entry


## PacePress®

prevention of  
hematoma after  
CIED implants



**MARKET**  
Licencing / Selling  
/ Partnership

# Project development in line with planned milestones






## H1 2025



**Awarded PLN 8.7 million in grants  
Pilot production begins**



**Obtaining CE MDR  
Completion of clinical trials**



**Submission of 510(k)  
application to FDA**



**Receipt of confirmed and  
verified devices**



**AtriClamp**



**PacePress®**



**CoolCryo®**



**MiniMax®**

## H2 2025/H1 2026

Animal testing begins

Obtaining the second CE MDR

Completion of recruitment in the  
clinical trial

Resumption of preclinical studies

## PacePress®





## Safer and faster recovery after implantations of Cardiac Implantable Electronic Devices

PacePress is pneumatic therapeutic medical device designed to minimize the risk of complications after CIED implantations, while ensuring patient comfort, mobility and recovery.

### Key features

- Reduces the risk of complications: infection and hematomas
- Shortens hospitalization
- Increases patient control and safety

**CE**

CE Marking  
a Medical Device



## 1.5 million procedures performed annually worldwide



About 60% of patients undergoing CIED implantation procedures are at risk of postoperative complications.

Approximately 10% of CIED procedures result in chest cavity haematomas, potentially leading to infection and re-operation.

Current prevention methods include:

- patient immobilization
- applying pressure to the implantation site

**CIED  
implantation site**





CoolCryo®



## Faster and more efficient cardiac cryoablation system

The CoolCryo® system is designed for the cryosurgical treatment of arrhythmic cardiac tissue ablation by freezing target tissues, inducing an inflammatory response (cryonecrosis) that blocks the electrical conduction pathway. Using liquid nitrogen makes cryoablation faster and more cost-effective.

### Key features


- at least four times faster and more efficient cryoablation
- possibility of minimally invasive endoscopic surgery
- possibility of continuous cryoablation and defrosting
- possibility of full-wall ablation of even thick tissues
- cheaper and more efficient cooling medium

**Clinical trial recruitment completed**  
**FDA 510(k) Substantive Review process ongoing**





# 510k Review – Procedure After Submission of the Application



Referencje:

1) FDA: 510(k) Submission Process, 10.03.2022



## 59 mln people worldwide suffer from arrhythmia

Arrhythmia ranks among the most prevalent heart conditions. It can result in circulatory failure and strokes.

The preferred treatment approach is ablation.


Currently, ablation treatments include:

- Cryoablation (CoolCryo®) – freezing method
- Radiofrequency (MiniMax®) or Pulsed Field – burning method





## MiniMax®





## Versatile RF ablation catheter offering 3D mapping and cooling

MiniMax® is a steerable, minimally invasive 2-in-1 catheter developed for the treatment of cardiac arrhythmias during RF ablation procedure. It combines ablation and 3D mapping functions to reduce both the risk and duration of the procedure. Additionally, it features cooling system using NaCl.

### Key features:

- 2 in 1 – Ablation + 3D electro-anatomical mapping
- Safer procedure – shorter time and lower risk
- Advanced NaCl cooling
- Flexible and steerable tip
- X-ray free – modern visualization





## AtriClamp





## Scalable Left Atrial Appendage Closure system

AtriClamp is a cardiothoracic clamp designed for the LAAC procedure. Utilizing an epicardial approach, it eliminates the need for threading through the appendage, keeping blood clots sealed within the appendage.

### Key features:

- low-cost and scalable production method
- fully retrievable & repositionable
- designed for single-handed operation
- no Dacron® used






## 15 million people affected annually

According to the World Health Organization, stroke is a leading cause of death, accounting for 11% of all deaths worldwide<sup>[1,2]</sup>.

The left atrial appendage closure procedure prevents 90% of embolic material, leading to 87% of strokes. This procedure will now be performed routinely with other cardiac surgeries, and we have therefore prioritized economic aspect of AtriClamp.




[3] Dudzińska-Szczerba, K., Association between left atrial appendage morphology and function and the risk of ischaemic stroke in patients with atrial fibrillation, *Arrhythmia & Electrophysiology Review* 11 (2022).

[1] World Health Organization - Fact sheets

[2] World Health Organization – Definitions: Stroke





Size and growth of the cardiac ablation market:

- The cardiac ablation market was valued at USD **3.5 billion** in **2022** and is projected to grow at a **CAGR of 13.5% over the next decade**.
- The valuation of the surgical cardiac ablation segment is estimated at around USD 1 billion (it is estimated that cryoablation accounts for 40–50% of this segment).

Key trends:

- Increasing number of patients with cardiovascular diseases, including cardiac arrhythmias.
- Minimally invasive procedures are the latest trend.
- Technological advancements in cardiac ablation devices.


Exponential growth in the number of procedures:

- Concomitant surgical ablation is currently a Class I recommendation for all patients undergoing their first elective cardiac surgery.
- Europe shows similarly favorable growth trends.

Number of surgical ablation procedures in the US:



Liczba zabiegów ablacji serca na świecie



Zródło: Rynek ablacji raport - Global Market Insights





Europe



USA




India  
(SAARC)

Number of CIED procedures

700K

600K


60K



- According to the American Heart Association, there are approximately 6.5 million people in the United States eligible for pacemaker implantation. Globally, this represents a potential of over 30 million procedures after which the use of PacePress® would be required.
- The number of pacemaker implantations indicates the potential demand for the therapeutic medical device PacePress®, as after each such procedure a pressure dressing is required to reduce the risk of hematoma formation in the pocket created for cardiac electrotherapy devices.
- Complications in the form of hematoma double the length of hospital stay; therefore, their elimination allows for performing twice as many procedures and generates cost savings through shorter hospitalization.
- As expected, this market is projected to grow steadily over the long term due to the aging population trend and, consequently, the overall increase in the number of patients treated in clinics and hospitals.




LAAO market value (USD billion):



Źródło: <https://www.precedenceresearch.com/left-atrial-appendage-closure-devices-market>

- The global market for left atrial appendage closure devices is expected to reach a value of approximately USD 7.01 billion by 2034, compared to USD 1.87 billion in 2024, with a compound annual growth rate (CAGR) of 14.12% over the period 2025-2034.  
The market for left atrial appendage closure devices in North America reached a value of USD 720 million in 2023.
- The growth of the market is supported by the increasing prevalence of atrial fibrillation and government initiatives. Technological development also supports the further growth of this market.

US LAAO Market Value (USD million)



Source: <https://www.precedenceresearch.com/left-atrial-appendage-closure-devices-market>

- The market for left atrial appendage closure devices in the United States reached a value of USD 620 million in 2024 and is projected to grow to approximately USD 2.36 billion by 2034, with a compound annual growth rate (CAGR) of 14.34% over the period 2025-2034.
- Based on the expert opinions of Prof. Piotr Suwalski and Prof. Paul Gründeman, it has been concluded that the development of the AtriClamp project is highly attractive due to its genuine competitive advantages and the commercialization potential of the device. Each year, competitors sell over 80,000 LAAO devices in the United States and Europe.
- It should also be noted that the true potential of the AtriClamp project lies in the market segment not yet addressed by competitors - namely, in less affluent countries that cannot afford the currently available devices due to their high cost.



## Advancing through the development process enhances the product's value



## Repeatable revenue model

### Growing demand

- Growing demand for minimally invasive technologies
  - Ageing population

### An experienced team

- Scientific Council composed of world-renowned scientists and inventors
- Experienced management and project teams


### Competitive advantages

- Diversified portfolio
- Patent protection future projects for development

## Two projects near commercialisation

### Large and healthy target market

- Potential buyers are global corporations
- The technologies under development fit in the portfolio of potential counterparties







*Patient friendly smart routing  
therapies for quality of life*

Thank you for your attention

---

[www.medinice.eu](http://www.medinice.eu)